The tissue-based genomic profiling market size is projected to be worth USD 1.2 billion in 2023. The market is likely to surpass USD 2.2 billion by 2033 at a CAGR of 6.6% during the forecast period. Due to increasing adoption of tissue based genomics by pharmaceutical and biotechnology companies along with growing clinical research procedures. Tissue-based genetic profiling is rapidly being used by pharmaceutical and biotechnology firms to discover prospective drug targets, plan clinical trials, and create companion diagnostics for their therapeutic products. Incorporating genetic profiling into medication development procedures improves therapy effectiveness and patient stratification.
In both clinical and scientific contexts, tissue-based genomic profiling is used. It aids in the diagnosis and monitoring of illnesses, the selection of relevant medicines, and the tracking of therapy responses in the clinical setting. It aids in the discovery of new biomarkers, the identification of pharmacological targets, and the creation of innovative therapeutic approaches in research.
Other Drivers Propelling the Demand for Tissue-based Genomic Profiling include:
Challenges for Companies /Manufacturers in the Tissue-based Genomic Profiling Market:
Opportunities in the Tissue-based Genomic Profiling Industry:
Latest Trends in the Tissue-based Genomic Profiling Market:
| Attributes | Details |
|---|---|
| Tissue-based Genomic Profiling Market Size (2023) | USD 1.2 Billion |
| Tissue-based Genomic Profiling Market Projected Size (2033) | USD 2.2 Billion |
| Value CAGR (2023 to 2033) | 6.6% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
From 2012 to 2022, the global tissue-based genomic profiling market experienced a CAGR of 5.0%, reaching a market size of USD 1.2 billion in 2023.
From 2012 to 2022, the global tissue-based genomic profiling industry witnessed steady growth due to the rising technological advancements in the tissue-based genomic profiling. Advances in genomic technology, such as next-generation sequencing (NGS), have fueled the expansion of tissue-based genomic profiling. These technologies have grown more accessible, cost-effective, and capable of analyzing massive volumes of genetic data, allowing for thorough tissue profiling.
Precision medicine, which includes personalizing therapies based on specific patient characteristics, has increased demand for tissue-based genetic profiling. Tissue genomic profiling reveals genetic changes, biomarkers, and therapeutic targets, enabling personalized treatment methods.
Future Forecast for Tissue-based Genomic Profiling Industry:
Looking ahead, the global tissue-based genomic profiling industry is expected to rise at a CAGR of 6.6% from 2023 to 2033. During the forecast period, the market size is expected to reach USD 2.2 billion.
The tissue-based genomic profiling industry is expected to continue its growth trajectory from 2023 to 2033, driven by increasing importance of liquid biopsy. The examination of circulating biomarkers in bodily fluids, known as liquid biopsy, is likely to develop significantly. Liquid biopsy is a non-invasive, real-time monitoring method for illness identification, treatment response evaluation, and minimal residual disease monitoring. Tissue-based genetic profiling will be critical in liquid biopsy diagnosis and personalized therapy decisions.
By allowing the examination of individual cells within a tissue sample, single-cell genomics has the potential to revolutionize tissue-based genetic profiling. This method will provide light on cellular heterogeneity, uncommon cell populations, and clonal development, allowing for a better understanding of disease progression, treatment response, and therapeutic resistance.
| Country | The United States |
|---|---|
| Market Size (USD million) by End of Forecast Period (2033) | USD 604.5 million |
| CAGR % 2023 to End of Forecast (2033) | 5.7% |
The tissue-based genomic profiling industry in the United States is expected to reach a market value of USD 604.5 million by 2033, expanding at a CAGR of 5.7%. The growing technological advancements in genomics in the United States can be ascribed to the country's increased market share. Government assistance in the form of financing and regulatory measures is important in driving the industry. Initiatives such as the National Institutes of Health's (NIH) Precision Medicine Initiative and the FDA's regulatory framework for genetic testing have a beneficial influence on the industry.
The United States is a world leader in genomics research, with a well-established infrastructure for genetic profiling. Next-generation sequencing (NGS), molecular diagnostics, and bioinformatics improvements all contribute to the growth of the tissue-based genomic profiling industry.
| Country | The United Kingdom |
|---|---|
| Market Size (USD million) by End of Forecast Period (2033) | USD 68.9 million |
| CAGR % 2023 to End of Forecast (2033) | 5.8% |
The tissue-based genomic profiling industry in the United Kingdom is expected to reach a market value of USD 68.9 million, expanding at a CAGR of 5.8% during the forecast period. The National Health Service in the United Kingdom is critical in advancing the use of tissue-based genetic profiling. Initiatives such as Genomics England's 100,000 Genomes Project aim to incorporate genomics into everyday healthcare and personalized treatment, ultimately driving the market.
| Country | China |
|---|---|
| Market Size (USD million) by End of Forecast Period (2033) | USD 102.1 million |
| CAGR % 2023 to End of Forecast (2033) | 6.4% |
The tissue-based genomic profiling industry in China is anticipated to reach a market value of USD 102.1 million, moving at a CAGR of 6.4 during the forecast period. The tissue-based genomic profiling industry in China is expected to grow prominently due to the increasing genomics research centers and government support. The Chinese government has made genomes research and precision medicine a priority. Initiatives like the Precision Medicine Initiative and the Healthy China 2030 plan encourage the use of genetic profiling in healthcare, propelling the market.
The Beijing Genomics Institute (BGI) and the Shanghai Genomic Institute are two of China's genomics research institutes. These centers contribute to genomic profiling technology research, development, and innovation, hence supporting market growth.
| Country | Japan |
|---|---|
| Market Size (USD million) by End of Forecast Period (2033) | USD 144.3 million |
| CAGR % 2023 to End of Forecast (2033) | 6.2% |
The tissue-based genomic profiling industry in Japan is estimated to reach a market value of USD 144.3 million by 2033, thriving at a CAGR of 6.2%. Japan has made tremendous advances in genomic research, developing low-cost genetic profiling methods. Because of the availability of low-cost sequencing technology and testing services, tissue-based genomic profiling is becoming more accessible to research institutions, fueling market expansion.
| Country | South Korea |
|---|---|
| Market Size (USD million) by End of Forecast Period (2033) | USD 73.2 Million |
| CAGR % 2023 to End of Forecast (2033) | 6.0% |
The tissue-based genomic profiling industry in South Korea is expected to reach a market value of USD 73.2 million, expanding at a CAGR of 6.0% during the forecast period. South Korea is a genomics research leader with a well-established genetic profiling infrastructure. Next-generation sequencing (NGS), molecular diagnostics, and bioinformatics improvements all contribute to the growth of the tissue-based genomic profiling industry.
Collaborations between the government, academia, and industry assist genomic profiling technology research, development, and commercialization. Partnerships between the public and private sectors boost innovation and market expansion.
Principal Consultant
The Tumor tissue and liquid DNA profiling is expected to dominate the tissue-based genomic profiling industry with a CAGR of 7.7% from 2023 to 2033. This segment captures a significant market share in 2023 and it is influenced by their unique advantages and applications. Tumor tissue profiling identifies particular genetic abnormalities in cancer cells, assisting in the precise diagnosis and categorization of distinct forms of cancer. Tissue-based genomic profiling can assist cancer patients find the best therapy choices by discovering actionable mutations or biomarkers that can be addressed with particular medicines. Liquid DNA profiling, on the other hand, can reveal genetic anomalies in the early stages of cancer, allowing for early intervention and therapy commencement. These reasons are increasing the market for Tumor tissue and Liquid DNA profiling.
The oncological diagnostics is expected to dominate the tissue-based genomic profiling industry with a CAGR of 6.5% from 2032 to 2033. This segment captures a significant market share in 2023 due to the non-invasive and early detection of cancer.
Genomic profiling has distinct benefits and complements in cancer therapy. Tissue profiling, for example, gives extensive information about the tumor's genetic landscape, whereas liquid DNA profiling provides non-invasive and dynamic monitoring capabilities. The desire for personalized care, improved patient outcomes, and advances in genetic technology are driving demand for both methods. Hence, this applications of genomic profiling in cancer detection, the demand is on the rise for oncological diagnostics over the forecast period.
The diagnostic laboratories are expected to dominate the tissue-based genomic profiling industry with a CAGR of 7.1%% from 2023 to 2033. This segment captures a significant market share in 2023 due to the enhanced accuracy of diagnosis.
Tissue-based genetic profiling enables diagnostic laboratories to provide more precise and personalized diagnostic and treatment recommendations, therefore enhancing patient care and results in a variety of illness areas, including cancer.
The tissue-based genomic profiling industry is highly competitive, with numerous players vying for market share. In such a scenario, key players in the tissue-based genomic profiling industry employ various strategies to stay competitive.
Key Strategies Adopted by the Players
Leading organisations spend in research and development to continuously enhance their genomic profiling technology. They aspire to create more sophisticated platforms, improve sequencing efficiency, data analysis capabilities, and the accuracy and sensitivity of genetic profiling tests. Staying on the cutting edge of technology innovations allows businesses to differentiate themselves and attract clients looking for the most up-to-date and dependable solutions.
Strategic alliances and cooperation with academic institutions, research organisations, and pharmaceutical businesses can increase a company's competitiveness. Collaborations allow major companies to gain access to innovative biomarkers, research findings, and knowledge, allowing them to provide cutting-edge solutions and remain at the forefront of innovation.
Key competitors are concentrating on broadening their market reach by expanding into new geographic regions and developing a strong worldwide presence. They may invest in the establishment of subsidiaries, distribution networks, or strategic partnerships in various countries in order to capitalize on developing market possibilities and obtain a competitive advantage over local competitors.
Key players in the tissue-based genomic profiling industry often engage in mergers and acquisitions to consolidate their market position, expand their product portfolio, and gain access to new markets.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Key Developments in the Tissue-based Genomic Profiling Market:
The growth potential of this market is 6.6% through 2033
China is projected to emerge as a lucrative market.
During 2012 to 2022, the market grew at a CAGR of 5%.
The United States is expected to reach market expansion at a CAGR of 5.7%.
Technological advancement in genomics research drives market growth in Japan.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Value Added Insights 5. Market Background 6. Global Market Demand (in Value or Size in USD Million) Analysis 2012 to 2022 and Forecast, 2023 to 2033 7. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Technology 7.1. Tumor Tissue and Liquid DNA Profiling 7.2. Sequencing Techniques 7.2.1. NGS 7.2.2. Sanger Sequencing 7.2.3. RNA Sequencing 7.3. Immunohistochemistry 7.4. Others 8. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Application 8.1. Personalized Medicine 8.2. Oncological Diagnostics 8.3. Research 8.3.1. Cancer Research 8.3.2. Biomarker Discovery 8.3.3. Others 9. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By End User 9.1. Research Institutes 9.2. Clinical Research Organizations 9.3. Hospitals & Clinics 9.4. Diagnostic Laboratories 9.5. Pharmaceutical & Biotechnology Companies 9.6. Others 10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Region 10.1. North America 10.2. Latin America 10.3. Europe 10.4. East Asia 10.5. South Asia 10.6. Oceania 10.7. Middle East and Africa (MEA) 11. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 12. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 13. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033 14. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 15. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 16. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033 17. Middle East and Africa (MEA) Market Analysis 2012 to 2022 and Forecast 2023 to 2033 18. Market Structure Analysis 19. Competition Analysis 19.1. FOUNDATION MEDICINE, INC. 19.2. Laboratory Corporation of America Holdings (Personal Genome Diagnostics Inc. (PGDx) 19.3. Illumina, Inc. 19.4. QIAGEN 19.5. Roche Diagnostics 19.6. Thermo Fisher Scientific 19.7. Exact Science 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Tissue-Based Genomic Profiling Market
